MA45552A - Compositions destinées au traitement de l'amylose - Google Patents

Compositions destinées au traitement de l'amylose

Info

Publication number
MA45552A
MA45552A MA045552A MA45552A MA45552A MA 45552 A MA45552 A MA 45552A MA 045552 A MA045552 A MA 045552A MA 45552 A MA45552 A MA 45552A MA 45552 A MA45552 A MA 45552A
Authority
MA
Morocco
Prior art keywords
amylosis
compositions
treatment
Prior art date
Application number
MA045552A
Other languages
English (en)
French (fr)
Inventor
Spencer D Guthrie
Gene G Kinney
Martin Koller
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of MA45552A publication Critical patent/MA45552A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA045552A 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose MA45552A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662357151P 2016-06-30 2016-06-30

Publications (1)

Publication Number Publication Date
MA45552A true MA45552A (fr) 2019-05-08

Family

ID=59351103

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045552A MA45552A (fr) 2016-06-30 2017-06-30 Compositions destinées au traitement de l'amylose

Country Status (16)

Country Link
US (2) US20190169280A1 (https=)
EP (1) EP3478713B1 (https=)
JP (3) JP2019519584A (https=)
CY (1) CY1125536T1 (https=)
DK (1) DK3478713T3 (https=)
ES (1) ES2914781T3 (https=)
HR (1) HRP20220979T8 (https=)
HU (1) HUE059400T2 (https=)
LT (1) LT3478713T (https=)
MA (1) MA45552A (https=)
PL (1) PL3478713T3 (https=)
PT (1) PT3478713T (https=)
RS (1) RS63446B1 (https=)
SI (1) SI3478713T1 (https=)
SM (1) SMT202200261T1 (https=)
WO (1) WO2018005967A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7217287B2 (ja) * 2018-03-23 2023-02-02 プロシーナ バイオサイエンシーズ リミテッド アミロイド症の処置および予防
JP2022520572A (ja) * 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のcd38細胞膜分子に対するモノクローナル抗体の組み合わせによるalアミロイドーシスの処置
EP4582446A3 (en) * 2019-03-05 2025-08-13 Prothena Biosciences Limited Methods of treating al amyloidosis
EP4022062A1 (en) * 2019-08-30 2022-07-06 Alnylam Pharmaceuticals, Inc. Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy
CA3187944A1 (en) * 2020-06-22 2021-12-30 Ngm Biopharmaceuticals, Inc. Lair-1-binding agents and methods of use thereof
TW202332465A (zh) * 2021-01-29 2023-08-16 愛爾蘭商普羅希那生物科學有限公司 治療al類澱粉變性症之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
DK2237803T3 (en) 2007-12-28 2015-10-05 Prothena Biosciences Ltd Treatment and prophylaxis of amyloidosis
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法

Also Published As

Publication number Publication date
EP3478713B1 (en) 2022-05-11
RS63446B1 (sr) 2022-08-31
SMT202200261T1 (it) 2022-07-21
HUE059400T2 (hu) 2022-11-28
PT3478713T (pt) 2022-05-27
US20210079078A1 (en) 2021-03-18
PL3478713T3 (pl) 2022-10-10
DK3478713T3 (da) 2022-06-20
ES2914781T3 (es) 2022-06-16
US20190169280A1 (en) 2019-06-06
WO2018005967A1 (en) 2018-01-04
SI3478713T1 (sl) 2022-06-30
JP2024127990A (ja) 2024-09-20
HRP20220979T1 (hr) 2022-11-11
EP3478713A1 (en) 2019-05-08
JP2019519584A (ja) 2019-07-11
HRP20220979T8 (hr) 2023-02-03
CY1125536T1 (el) 2025-05-09
LT3478713T (lt) 2022-06-10
JP2022121658A (ja) 2022-08-19

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45192A (fr) Traitement d'association
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3448875A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3370721A4 (en) TREATMENT OF OSTEOARTHRITIS
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
MA46524A (fr) Composés de biphényl-sulfonamide destinés au traitement de néphropathies
EP3541408A4 (en) COMPOSITIONS AND METHODS FOR TREATING ABERRATING ANGIOGENS
EP3443094A4 (en) PROCESS FOR REDUCING C9ORF72 EXPRESSION
FR3056393B1 (fr) Orthese d'extension de machoires
MA45552A (fr) Compositions destinées au traitement de l'amylose
EP3541379A4 (en) COMPOSITIONS FOR THE TREATMENT OF HYPERTONIA
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3344256A4 (en) COMPOSITIONS FOR TREATMENT OF JOINTS
EP3538219A4 (en) TOPICAL COMPOSITION FOR TREATING ACNE
PL3573620T3 (pl) Kompozycje do leczenia nadciśnienia
EP3716966A4 (en) ALPHA-KETO ACID COMPOSITIONS FOR THE TREATMENT OF HYPOALBUMINEMIA
EP3347032A4 (en) TREATMENT OF ASZITES
EP3655036C0 (en) COMPOSITIONS FOR THE TREATMENT OF STRESS-RELATED DISORDERS
EP3270968C0 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
EP3344650A4 (en) AAV-EPO FOR THE TREATMENT OF PETS
EP3373922A4 (en) COMPOSITIONS AND METHODS FOR TREATING HOMOCYSTINURIA
EP3632430A4 (en) AGENTS FOR THE PREVENTION OR TREATMENT OF SPINOCERBELLARY ATAXIA